Company intelligence / Profile preview

Apollo Labs

Cambridge, United Kingdom

Ownership: Private
Development stage: Other

Overview

As of early 2024, Apollo Therapeutics transitioned into a multi-clinical asset company with at least four programs in clinical development, including an acquired anti-IL-18 mAb (camoteskimab/AP43) for inflammatory diseases

Therapeutic areas: OtherDermatology
Modalities: Monoclonal antibodySmall moleculeProteinBiologic
Industry: Biotech

Partnerships

University of CambridgeUniversity of OxfordImperial College LondonUniversity College LondonKings College LondonThe Institute of Cancer ResearchJohnson & JohnsonGSKAstraZeneca

Beyond the preview

Go deeper on Apollo Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apollo Labs.

Explore the full profile